ISIS Pharmaceuticals (NASDAQ:ISIS) announced its earnings results on Monday. The company reported ($0.10) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.12) by $0.02, StockRatingsNetwork reports. The company had revenue of $57.08 million for the quarter, compared to the consensus estimate of $45.60 million. During the same quarter in the previous year, the company posted ($0.09) earnings per share. The company’s revenue for the quarter was up 49.8% on a year-over-year basis.
In other ISIS Pharmaceuticals news, CEO Stanley T. Crooke unloaded 16,000 shares of ISIS Pharmaceuticals stock on the open market in a transaction that occurred on Friday, August 1st. The stock was sold at an average price of $30.53, for a total transaction of $488,480.00. The transaction was disclosed in a filing with the SEC, which is available at this link.
Shares of ISIS Pharmaceuticals (NASDAQ:ISIS) opened at 30.40 on Monday. ISIS Pharmaceuticals has a 52-week low of $22.25 and a 52-week high of $62.66. The stock has a 50-day moving average of $32.45 and a 200-day moving average of $38.23. The company’s market cap is $3.574 billion.
A number of research firms have recently commented on ISIS. Analysts at Zacks reiterated a “neutral” rating on shares of ISIS Pharmaceuticals in a research note on Thursday, June 5th. They now have a $29.00 price target on the stock. On a related note, analysts at Summer Street reiterated a “neutral” rating on shares of ISIS Pharmaceuticals in a research note on Friday, May 23rd. Finally, analysts at TheStreet downgraded shares of ISIS Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Thursday, May 8th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and five have assigned a buy rating to the stock. ISIS Pharmaceuticals currently has an average rating of “Hold” and an average target price of $41.10.
Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.